한글목차

세계의 siRNA 의약품 시장 규모는 2023년에 15억 9,651만 달러로 평가되었습니다.

이 시장은 2030년에는 128억 9,237만 달러에 이를 것으로 예측되며, 예측 기간인 2024-2030년간 CAGR은 31.94%를 나타낼 전망입니다.

미국의 siRNA 의약품 시장 규모는 2023년에 9억 204만 달러로 평가되었습니다. 이 시장은 2024년부터 2030년까지 예측 기간 중에 25.58%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 52억 2,055만 달러에 이를 것으로 예측됩니다.

유럽의 siRNA 의약품 시장 규모는 2023년에 5억 585만 달러로 평가되었습니다. 이 시장은 2024년부터 2030년까지 예측 기간 중에 34.51%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 45억 4,073만 달러에 이를 것으로 예측됩니다.

기타 지역의 siRNA 의약품 시장 규모는 2023년에 1억 8,862만 달러로 평가되었습니다. 이 시장은 2024년부터 2030년까지 예측 기간 중에 44.32%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 31억 3,109만 달러에 이를 것으로 예측됩니다.

세계의 siRNA 의약품 시장에 대해 조사했으며, 시장 개요와 함께 유형별/용도별/지역별 동향 및 시장 진출기업 개요 등의 정보를 제공합니다.

목차

제1장 siRNA 의약품 시장 개요

• siRNA 의약품 시장 개요
• 세계의 siRNA 의약품 시장 규모 개요, 지역별, 2019년 vs. 2023년 vs. 2030년
• siRNA 의약품 시장 규모, 지역별(2019년-2030년)
• 주요 지역 siRNA 의약품 시장 규모(2019년-2030년)

제2장 siRNA 의약품 시장, 유형별

• 서론
• 세계의 siRNA 의약품 시장 규모, 유형별 : 2019년 vs. 2023년 vs. 2030년
• 주요 지역 시장 규모, 유형별

제3장 siRNA 의약품 시장 개요, 용도별

• 서론
• 세계의 siRNA 의약품 시장 규모, 용도별 : 2019년 vs. 2023년 vs. 2030년
• 주요 지역 시장 규모, 용도별

제4장 FDA 승인 siRNA 의약품

제5장 siRNA 의약품 경쟁 분석

제6장 미국

제7장 유럽

제8장 기타 지역

제9장 주요 기업 개요

• Alnylam
• Novartis
• Novo Nordisk
• Genzyme
• Arrowhead
• Silence
• Sylentis
• Avidity Biosciences
• Sirnaomics

제10장 siRNA 의약품 산업 체인, 주요 원재료 및 Upstream 비용 분석

제11장 siRNA 의약품 시장 역학

• siRNA 의약품 업계 동향
• siRNA 의약품 시장 성장 촉진요인
• siRNA 의약품 시장이 해결해야 할 과제
• siRNA 의약품 시장 성장 억제요인

제12장 siRNA 의약품 개발 실적과 향후 전망

제13장 조사 결과/결론

제14장 조사 방법과 데이터 소스

영문목차

The global market for siRNA Drug estimated was at US$ 1,596.51 million in the year 2023, is projected to reach a revised size of US$ 12,892.37 million by 2030, growing at a CAGR of 31.94% during the forecast period 2024-2030.

United States market for siRNA Drug was valued at $ 902.04 million in 2023 and will reach $ 5,220.55 million by 2030, at a CAGR of 25.58% during the forecast period of 2024 through 2030.

Europe market for siRNA Drug was valued at $ 505.85 million in 2023 and will reach $ 4,540.73 million by 2030, at a CAGR of 34.51 % during the forecast period of 2024 through 2030.

Rest of World market for siRNA Drug was valued at $ 188.62 million in 2023 and will reach $ 3,131.09 million by 2030, at a CAGR of 44.32 % during the forecast period of 2024 through 2030.

This report aims to provide a comprehensive presentation of the global market for siRNA Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding siRNA Drug.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global siRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

Market Segmentation

This report covers the siRNA Drug segments by company, by Type, by Application, by region and country, and provides market size and CAGR for the history and forecast period (2019-2024, 2025-2030), considering 2023 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

By Company

• Alnylam
• Novartis
• Novo Nordisk
• Genzyme
• Arrowhead
• Silence
• Sylentis
• Avidity Biosciences
• Sirnaomics

Segment by Type

• Intravenous Injection
• Subcutaneous Injection

Segment by Application

• Nervous System Therapy
• Endocrine and Metabolic Therapy
• Others

By Region

• United States
• Rest of World
• Canada
• Japan
• Brazil
• China
• Australia
• Europe
• Germany
• France
• U.K.
• Italy
• Switzerland
• Nordic Countries
• Rest of Europe

Chapter Outline

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2019-2024, 2025-2030). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter Four: Details of FDA-Approved siRNA Drugs

Chapter Five: Detailed analysis of siRNA Drug companies' competitive landscape, revenue, market share and ranking, etc.

Chapter Six, Seven and Eight: United States, Europe and rest of world revenue by country.

Chapter Nine: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter Ten: Provides siRNA Drug Industry Chain, Key Raw Materials and Upstream Cost Analysis

Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter Twelve: About siRNA Drug Development History and Future Outlook

Chapter Thirteen: Research Finding/Conclusion

Table of Contents

1 Market Overview of siRNA Drug

• 1.1 siRNA Drug Market Overview
  • 1.1.1 siRNA Drug Product Scope
  • 1.1.2 siRNA Drug Market Status and Outlook
• 1.2 Global siRNA Drug Market Size Overview by Region 2019 VS 2023 VS 2030
• 1.3 Global siRNA Drug Market Size by Region (2019-2030)
  • 1.3.1 Global siRNA Drug Historic Market Size by Region (2019-2024)
  • 1.3.2 Global siRNA Drug Market Size Forecast by Region (2025-2030)
• 1.4 Key Regions siRNA Drug Market Size (2019-2030)
  • 1.4.1 United States siRNA Drug Market Size (2019-2030)
  • 1.4.2 Europe siRNA Drug Market Size (2019-2030)
  • 1.4.3 Rest of World siRNA Drug Market Size (2019-2030)

2 siRNA Drug Market by Type

• 2.1 Introduction
  • 2.1.1 Intravenous Injection
  • 2.1.2 Subcutaneous Injection
• 2.2 Global siRNA Drug Market Size by Type: 2019 VS 2023 VS 2030
  • 2.2.1 Global siRNA Drug Historic Market Size by Type (2019-2024)
  • 2.2.2 Global siRNA Drug Forecasted Market Size by Type (2025-2030)
• 2.3 Key Regions Market Size by Type
  • 2.3.1 United States siRNA Drug Revenue Breakdown by Type (2019-2030)
  • 2.3.2 Europe siRNA Drug Revenue Breakdown by Type (2019-2030)
  • 2.3.3 Rest of World siRNA Drug Revenue Breakdown by Type (2019-2030)

3 siRNA Drug Market Overview by Application

• 3.1 Introduction
  • 3.1.1 Nervous System Therapy
  • 3.1.2 Endocrine and Metabolic Therapy
  • 3.1.3 Others
• 3.2 Global siRNA Drug Market Size by Application: 2019 VS 2023 VS 2030
  • 3.2.1 Global siRNA Drug Historic Revenue by Application (2019-2024)
  • 3.2.2 Global siRNA Drug Forecasted Revenue by Application (2025-2030)
• 3.3 Key Regions Market Size by Application
  • 3.3.1 United States siRNA Drug Revenue Breakdown by Application (2019-2030)
  • 3.3.2 Europe siRNA Drug Revenue Breakdown by Application (2019-2030)
  • 3.3.3 Rest of World siRNA Drug Revenue Breakdown by Application (2019-2030)

4 FDA-Approved siRNA Drugs

5 siRNA Drug Competition Analysis by Players

• 5.1 Global siRNA Drug Market Size by Players (2019-2024)
• 5.2 Global Top Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drug as of 2023)
• 5.3 Global Key Players of siRNA Drug Head office
• 5.4 Global Key Players of siRNA Drug and Product Research Progress
• 5.5 Global Key Players of siRNA Drug and Establishment Time
• 5.6 siRNA Drug Market Concentration Rate

6 United States

• 6.1 United States siRNA Drug Market Size (2019-2030)
• 6.2 United States

7 Europe

• 7.1 Europe siRNA Drug Market Size by Country (2019-2030)
• 7.2 Germany
• 7.3 France
• 7.4 U.K.
• 7.5 Italy
• 7.6 Switzerland
• 7.7 Nordic Countries
• 7.8 Rest of Europe

8 Rest of World

• 8.1 Rest of World siRNA Drug Market Size by Region (2019-2030)
• 8.2 Canada
• 8.3 Japan
• 8.4 Brazil
• 8.5 China
• 8.6 Australia

9 Company (Top Players) Profiles

• 9.1 Alnylam
  • 9.1.1 Alnylam Profile
  • 9.1.2 Alnylam Main Business
  • 9.1.3 Alnylam siRNA Drug Products, Services and Solutions
  • 9.1.4 Alnylam siRNA Drug Revenue (US$ Million) & (2019-2024)
  • 9.1.5 Alnylam Recent Developments
• 9.2 Novartis
  • 9.2.1 Novartis Profile
  • 9.2.2 Novartis Main Business
  • 9.2.3 Novartis siRNA Drug Products, Services and Solutions
  • 9.2.4 Novartis siRNA Drug Revenue (US$ Million) & (2019-2024)
  • 9.2.5 Novartis Recent Developments
• 9.3 Novo Nordisk
  • 9.3.1 Novo Nordisk Profile
  • 9.3.2 Novo Nordisk Main Business
  • 9.3.3 Novo Nordisk siRNA Drug Products, Services and Solutions
  • 9.3.4 Novo Nordisk siRNA Drug Revenue (US$ Million) & (2019-2024)
  • 9.3.5 Novo Nordisk Recent Developments
• 9.4 Genzyme
  • 9.4.1 Genzyme Profile
  • 9.4.2 Genzyme Main Business
  • 9.4.3 Genzyme siRNA Drug Products, Services and Solutions
  • 9.4.4 Genzyme Recent Developments
• 9.5 Arrowhead
  • 9.5.1 Arrowhead Profile
  • 9.5.2 Arrowhead Main Business
  • 9.5.3 Arrowhead siRNA Drug Products, Services and Solutions
  • 9.5.4 Arrowhead Recent Developments
• 9.6 Silence
  • 9.6.1 Silence Profile
  • 9.6.2 Silence Main Business
  • 9.6.3 Silence siRNA Drug Products, Services and Solutions
  • 9.6.4 Silence Recent Developments
• 9.7 Sylentis
  • 9.7.1 Sylentis Profile
  • 9.7.2 Sylentis Main Business
  • 9.7.3 Sylentis siRNA Drug Products, Services and Solutions
  • 9.7.4 Sylentis Recent Developments
• 9.8 Avidity Biosciences
  • 9.8.1 Avidity Biosciences Profile
  • 9.8.2 Avidity Biosciences Main Business
  • 9.8.3 Avidity Biosciences siRNA Drug Products, Services and Solutions
  • 9.8.4 Avidity Biosciences Recent Developments
• 9.9 Sirnaomics
  • 9.9.1 Sirnaomics Profile
  • 9.9.2 Sirnaomics Main Business
  • 9.9.3 Sirnaomics siRNA Drug Products, Services and Solutions
  • 9.9.4 Sirnaomics Recent Developments

10 siRNA Drug Industry Chain, Key Raw Materials and Upstream Cost Analysis

• 10.1 siRNA Drug Industrial Chain Analysis
• 10.2 siRNA Drug Key Raw Materials
• 10.3 Upstream Cost Proportion

11 siRNA Drug Market Dynamics

• 11.1 siRNA Drug Industry Trends
• 11.2 siRNA Drug Market Drivers
• 11.3 siRNA Drug Market Challenges
• 11.4 siRNA Drug Market Restraints

12 siRNA Drug Development History and Future Outlook

• 12.1 Evolution of siRNA Drug
• 12.2 Mechanism of siRNA Drug: Targeted Gene Silencing with High Specificity
• 12.3 Limitations and Improvement Strategies of siRNA Drug

13 Research Finding/Conclusion

14 Methodology and Data Source

• 14.1 Methodology/Research Approach
  • 14.1.1 Research Programs/Design
  • 14.1.2 Market Size Estimation
  • 14.1.3 Market Breakdown and Data Triangulation
• 14.2 Data Source
  • 14.2.1 Secondary Sources
  • 14.2.2 Primary Sources
• 14.3 Author List
• 14.4 Disclaimer